Thompson et al., 2017 - Google Patents
Non-human primates as a model for understanding the mechanism of action of toll-like receptor-based vaccine adjuvantsThompson et al., 2017
- Document ID
- 1085932687752173816
- Author
- Thompson E
- Loré K
- Publication year
- Publication venue
- Current Opinion in Immunology
External Links
Snippet
Highlights•TLR based adjuvants increase immunogenicity of non-live vaccines.•NHP cell subset phenotype and TLR expression reflects humans.•NHP model better translates immunogenicity of TLR adjuvants to clinic.•TLR adjuvants can fine tune innate immune …
- 229960005486 vaccines 0 title abstract description 78
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Thompson et al. | Non-human primates as a model for understanding the mechanism of action of toll-like receptor-based vaccine adjuvants | |
| AU2020230277B2 (en) | Combination therapy with neoantigen vaccine | |
| Fotin‐Mleczek et al. | Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect | |
| Thompson et al. | TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25 | |
| Kreiter et al. | Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity | |
| Stevenson et al. | DNA vaccines against cancer come of age | |
| Kedl et al. | Epitope dominance, competition and T cell affinity maturation | |
| Cheng et al. | TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs | |
| Trumpfheller et al. | The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine | |
| Kornbluth et al. | Immunostimulatory combinations: designing the next generation of vaccine adjuvants | |
| Rittig et al. | Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy | |
| Karkada et al. | Therapeutic vaccines and cancer: focus on DPX-0907 | |
| CY1107802T1 (en) | COMPOSITIONS AND METHODS FOR INDUCING SPECIFIC CELLULAR RESPONSES OF T-Lymphocytes | |
| Junqueira et al. | Trypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccine | |
| Spearman et al. | Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial | |
| Maletto et al. | CpG-DNA stimulates cellular and humoral immunity and promotes Th1 differentiation in aged BALB/c mice | |
| Karbach et al. | Therapeutic administration of a synthetic CpG oligodeoxynucleotide triggers formation of anti-CpG antibodies | |
| TW202237625A (en) | Hiv vaccines and methods of making and using | |
| McCluskie et al. | CpG ODN and ISCOMATRIX Adjuvant: A Synergistic Adjuvant Combination Inducing Strong T‐Cell IFN‐γ Responses | |
| EP2351577A1 (en) | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs | |
| Muthumani et al. | Co‐immunization with an optimized plasmid‐encoded immune stimulatory interleukin, high‐mobility group box 1 protein, results in enhanced interferon‐γ secretion by antigen‐specific CD8 T cells | |
| US20230034677A1 (en) | Novel immunotherapies targeting pd-1 with anti-pd-1/il-15 immunocytokines | |
| Flamar et al. | HIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: A comparative study of prototype dendritic cell targeting therapeutic vaccine candidates | |
| Pudney et al. | DNA vaccination with T‐cell epitopes encoded within Ab molecules induces high‐avidity anti‐tumor CD8+ T cells | |
| Kallinteris et al. | Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100 (48-58) MHC class II epitope |